Next Article in Journal
Mito-Nuclear Communication in Hepatocellular Carcinoma Metabolic Rewiring
Previous Article in Journal
Kallikrein 12 Regulates Innate Resistance of Murine Macrophages against Mycobacterium bovis Infection by Modulating Autophagy and Apoptosis
Previous Article in Special Issue
Hepatitis C Virus Infection: Host–Virus Interaction and Mechanisms of Viral Persistence
Article Menu

Export Article

Open AccessCase Report

Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4

1
Department of Health Sciences, Unit of Clinical Microbiology, “Magna Graecia” University, 88100 Catanzaro, Italy
2
Department of Medical and Surgical Sciences, Unit of Infectious and Tropical Diseases, “Magna Graecia” University, 88100 Catanzaro, Italy
3
Institute for Experimental Veterinary Medicine of Southern Italy, 88100 Catanzaro, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cells 2019, 8(5), 416; https://doi.org/10.3390/cells8050416
Received: 29 March 2019 / Revised: 27 April 2019 / Accepted: 3 May 2019 / Published: 5 May 2019
(This article belongs to the Special Issue Hepatitis C Virus and Host Interactions)
  |  
PDF [1084 KB, uploaded 5 May 2019]
  |     |  

Abstract

Direct-acting antiviral drugs to cure infections with Hepatitis C virus (HCV) achieve a sustained virological response (SVR) in more than 90% of adult patients. At present, clinical trials are ongoing and real-life data are still limited in children. Herein, we report two cases of pediatric patients treated with fixed-dose combination of sofosbuvir/ledipasvir, already approved to treat HCV4 genotype. Both young girls achieved SVR even though HCV4 isolates carried L28M and M31L NS5A resistance-associated substitutions (RASs). Therefore, possible effects of these RASs merit further study, especially in children. View Full-Text
Keywords: pediatric patients; Hepatitis C virus 4; sofosbuvir/ledipasvir pediatric patients; Hepatitis C virus 4; sofosbuvir/ledipasvir
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Marascio, N.; Mazzitelli, M.; Pavia, G.; Giancotti, A.; Barreca, G.S.; Costa, C.; Pisani, V.; Greco, G.; Serapide, F.; Trecarichi, E.M.; Casalinuovo, F.; Liberto, M.C.; Matera, G.; Torti, C. Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4. Cells 2019, 8, 416.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top